Endocannabinoid Membrane Transport (Contested)

Say the uncertainty first contested in vitro

Anandamide and 2-AG are lipids. A lipid does not need a transporter to cross a membrane in the way a charged amino acid does, which is the source of the whole difficulty. Cellular uptake of anandamide has been measured for thirty years and has the hallmarks of a facilitated process: it is temperature-sensitive, saturable, selective between structurally similar lipids, and inhibitable by compounds that do not inhibit the hydrolytic enzymes. Yet no protein performing the transport has been cloned, and there is direct evidence against a classical saturable transporter of the monoamine type. This page therefore reports a live scientific dispute rather than a mechanism, and anything downstream that depends on the mechanism being settled should be treated as unsupported.

Contested — caveat. The mechanism of endocannabinoid membrane transport is an open question in the primary literature. Statements of the form "compound X blocks the endocannabinoid transporter" assume a carrier whose existence is not established.

Sources: Glaser ST 2003 · Chicca A 2012

The three competing accounts contested in vitro

The first account is simple diffusion driven by a concentration gradient that FAAH itself maintains: anandamide crosses the membrane passively, FAAH destroys it on the inside, the intracellular concentration is held near zero, and the resulting gradient makes uptake look saturable and carrier-like because it tracks enzyme activity rather than a transporter. Glaser and colleagues argued this position directly in 2003 in a paper titled, unambiguously, evidence against the presence of an anandamide transporter. The second account holds that a dedicated membrane carrier exists and simply has not been identified yet; the strongest support is that selective uptake inhibitors exist which do not inhibit FAAH or MAGL, and that transport is bidirectional in a way pure sink-driven diffusion does not easily explain — Chicca and colleagues reported that bidirectionality in 2012. The third account moves the specificity inside the cell: Kaczocha, Glaser and Deutsch identified fatty-acid-binding proteins, particularly FABP5 and FABP7, as intracellular carriers that shuttle anandamide from the membrane to FAAH on the endoplasmic reticulum, in which case what looks like transport inhibition may in part be interference with intracellular trafficking. These are not mutually exclusive, and the current state of the field is best described as all three contributing in proportions that are not agreed.

Contested — caveat. Three live hypotheses, not a settled hierarchy. The table states each position and its weakness rather than picking one.

Sources: Glaser ST 2003 · Chicca A 2012 · Kaczocha M 2009

Guineensine: the mechanistically clean case animal

Guineensine is an isobutylamide alkaloid of Piper nigrum and related Piper species. Nicolussi and colleagues reported in 2014 that it inhibits cellular endocannabinoid uptake with an EC50 of approximately 290 nM — nanomolar potency, which is unusual for a plant natural product acting on this system — and, crucially, that it does NOT inhibit FAAH or MAGL and does not bind the cannabinoid receptors appreciably. That selectivity is what makes it valuable. A compound that inhibits uptake without inhibiting the hydrolases is a direct argument against the pure FAAH-driven-diffusion account, because there is nothing left for it to be doing to the gradient. In mice, guineensine produced cannabimimetic behavioural effects that were attenuated by a CB1 antagonist, indicating that the uptake inhibition translates into increased receptor signalling in vivo. It remains a pharmacological probe rather than a therapy: the mouse work is behavioural and anti-inflammatory, there is no human data, and its presence in black pepper does not establish that eating black pepper achieves the relevant concentration.

• EC50 approximately 290 nM for endocannabinoid uptake inhibition.
• No FAAH inhibition, no MAGL inhibition, no appreciable receptor binding — mechanistically clean.
• Cannabimimetic behavioural effects in mice, CB1-dependent.
• No human pharmacokinetic or efficacy data. Dietary relevance unestablished.

Sources: Nicolussi S 2014

WOBE437 and the Echinacea scaffold animal

The synthetic side of this story starts in a plant as well. Raduner and colleagues showed in 2006 that the N-alkylamides of Echinacea are cannabinomimetics, binding CB2 and modulating endocannabinoid signalling — the first demonstration that this structural class engages the system. The 2,4-dodecadienamide scaffold from that work was developed into selective endocannabinoid reuptake inhibitors, and Chicca and colleagues reported the optimised chemical probes in 2017, of which WOBE437 is the reference compound: a selective inhibitor of endocannabinoid cellular reuptake that raises endocannabinoid levels without inhibiting the hydrolases. Reynoso-Moreno and colleagues then showed in 2021 that WOBE437 reduced disease progression in a mouse model of multiple sclerosis. The line from Echinacea alkylamide to selective probe to disease-model efficacy is a good illustration of why the botanical side of this shelf is research material rather than decoration — and the probe is still a probe: mouse data, no human trials.

Sources: Raduner S 2006 · Chicca A 2017 · Reynoso-Moreno I 2021

Macamides: uptake and FAAH together contested in vitro

The macamides of Lepidium meyenii (maca) are N-benzyl fatty-acid amides — structurally, they are fatty-acid amides, which is to say they resemble the enzyme substrate. Wu and colleagues evaluated macamides and synthetic analogues as FAAH inhibitors in vitro and confirmed activity for the class, with structure-activity relationships across chain length and unsaturation. Anandamide uptake inhibition has also been reported for macamides, with an IC50 in the region of 670 nM carried in the operator corpus. Unlike guineensine, then, macamides are not a clean single-mechanism probe: they act at the enzyme and at the uptake step, which makes them more interesting ethnobotanically and less useful for deciding what the transport mechanism is.

Contested — caveat. The 670 nM anandamide-uptake IC50 for macamides is carried from the operator corpus and was not traced to a primary measurement during compilation. The FAAH inhibition is documented in Wu et al. 2013; the uptake figure should be treated as unverified.

Sources: Wu H 2013 · Van Kush Family Research Institute 2026*

FABP5 and the cannabidiol hypothesis contested in vitro

If fatty-acid-binding proteins carry anandamide to FAAH, then anything that competes for the FABP binding site should slow anandamide clearance without inhibiting FAAH itself. Elmes and colleagues reported in 2015 that Δ9-THC and cannabidiol are both FABP ligands and that cannabidiol competitively inhibits FABP-mediated anandamide transport, proposing this as a mechanism by which cannabidiol raises anandamide levels. This is one of the more plausible mechanistic accounts of a compound whose pharmacology is otherwise notoriously promiscuous, and it is not the only proposed route to the same endpoint. Treat it as a well-motivated hypothesis with in-vitro support rather than an established mechanism of cannabidiol action in humans.

Contested — caveat. In-vitro competition data plus a mechanistic argument. Cannabidiol has many reported molecular targets and the relative contribution of FABP competition to its effects in humans is not established.

Sources: Elmes MW 2015 · Kaczocha M 2009